Harmanjot Grewal, MD

  • A Long-term, open-label follow-up study of tofocitinib (CP-690,550), for treatment of rheumatoid arthritis
    • Not actively enrolling
  • A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Four 12-Week Treatment Cycles (48 Weeks Total) of Epratuzumab in Systemic Lupus Erythematosus Subjects with Moderate to Severe Disease (EMBODY 2)
    • Not actively enrolling

Luis Espinoza, MD

  • Combination Therapy for Chlamydia-Induced Reactive Arthritis